- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04822064
Comparison of Oral Chloral Hydrate and Combination of Intranasal Dexmedetomidine and Ketamine for Rescue After Failed Pediatric Procedural Sedation
Comparison of Oral Chloral Hydrate and Combination of Intranasal Dexmedetomidine and Ketamine for Rescue After Failed Pediatric Procedural Sedation: a Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jin-Tae Kim, MD. PhD
- Phone Number: 82-2-2072-3664
- Email: jintae73@gmail.com
Study Locations
-
-
-
Seoul, Korea, Republic of
- Jin-Tae Kim
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pediatric patients who need procedural sedation (Age < 7 years)
- ASA (American Society of Anesthesiologists) physical status 1-3
- Failed to induce sedation with oral chloral hydrate 50mg/kg
Exclusion Criteria:
- ASA (American Society of Anesthesiologists) physical status 4-5
- History of hypersensitivity to Dexmedetomidine, Ketamine, or Chloral hydrate
- Recent administration of Alpha 2 adrenergic receptor agonist or antagonist
- Cannot administrate oral medication (e.g. Swallowing difficulty)
- Cannot administrate intranasal medication(e.g. Excessive rhinorrhea)
- Unstable vital signs, Unstable arrhythmia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: intranasal dexmedetomdine and kemtaine
Additional intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to induce rescue sedation (pediatric sedation state scale = 1,2,3) after failed sedation attempt (PSSS=4,5) with oral chloral hydrate (50mg/kg)
|
Additional intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to induce rescue sedation (pediatric sedation state scale = 1,2,3) after failed sedation attempt (PSSS=4,5) with oral chloral hydrate (50mg/kg)
|
Active Comparator: oral chloral hydrate
Additional oral chloral hydrate (50mg/kg) administration to induce rescue sedation (pediatric sedation state scale = 1,2,3) after failed sedation attempt (PSSS=4,5) with oral chloral hydrate (50mg/kg)
|
Additional oral chloral hydrate (50mg/kg) administration to induce rescue sedation (pediatric sedation state scale = 1,2,3) after failed sedation attempt (PSSS=4,5) with oral chloral hydrate (50mg/kg)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Success rate of adequate rescue sedation (PSSS = 1, 2, 3) within 15 minutes %
Time Frame: During pediatric procedural sedation (up to 1 hour)
|
Success rate of adequate rescue sedation (Pediatric Sedation State Scale= 1,2,3) within 15 minutes after sedative administration.
%
|
During pediatric procedural sedation (up to 1 hour)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PSSS(Pediatric Sedation State Scale, 0-5)
Time Frame: During pediatric procedural sedation (up to 3 hour)
|
5 Patient is moving in a manner that impedes the proceduralist and requires forceful immobilization. 4 Moving during the procedure that requires gentle immobilization for positioning. 3 Expression of pain or anxiety on face, but not moving or impeding completion of the procedure. 2 Quiet (asleep or awake), not moving during procedure, and no frown (or brow furrow) indicating pain or anxiety. 1 Deeply asleep with normal vital signs, but requiring airway intervention and/or assistance 0 Sedation associated with abnormal physiologic parameters that require acute intervention q 10min |
During pediatric procedural sedation (up to 3 hour)
|
SpO2 during sedation (%)
Time Frame: During pediatric procedural sedation (up to 3 hour)
|
SpO2(%) by pulse oximetry at Baseline(T0), q 10min
|
During pediatric procedural sedation (up to 3 hour)
|
Respiratory rate during sedation (/min)
Time Frame: During pediatric procedural sedation (up to 3 hour)
|
RR(/min) at Baseline(T0), q 10min
|
During pediatric procedural sedation (up to 3 hour)
|
the incidence of PSSS=0 (Abnormal physiologic parameter that require acute intervention) %
Time Frame: During pediatric procedural sedation (up to 3 hour)
|
the incidence of PSSS=0 (Abnormal physiologic parameter that require acute intervention) %
|
During pediatric procedural sedation (up to 3 hour)
|
The incidence of significant desaturation (SpO2 < 95% or -10% from baseline, >10 seconds) %
Time Frame: During pediatric procedural sedation (up to 3 hour)
|
The incidence of significant desaturation (SpO2 < 95% or -10% from baseline, >10 seconds) %
|
During pediatric procedural sedation (up to 3 hour)
|
The incidence of significant apnea (>20seconds) %
Time Frame: During pediatric procedural sedation (up to 3 hour)
|
The incidence of significant apnea (>20seconds) %
|
During pediatric procedural sedation (up to 3 hour)
|
The lowest SpO2 value (%)
Time Frame: During pediatric procedural sedation (up to 3 hour)
|
The lowest SpO2 value (%)
|
During pediatric procedural sedation (up to 3 hour)
|
The incidence of hemodynamic intervention: fluid management, intravenous medication %
Time Frame: During pediatric procedural sedation (up to 3 hour)
|
The incidence of hemodynamic intervention: fluid management, intravenous medication %
|
During pediatric procedural sedation (up to 3 hour)
|
The incidence of significant bradycardia (-30% from baseline) %
Time Frame: During pediatric procedural sedation (up to 3 hour)
|
The incidence of significant bradycardia (-30% from baseline) %
|
During pediatric procedural sedation (up to 3 hour)
|
The incidence of significant hypotension (-30% from baseline) %
Time Frame: During pediatric procedural sedation (up to 3 hour)
|
The incidence of significant hypotension (-30% from baseline) %
|
During pediatric procedural sedation (up to 3 hour)
|
Patients' acceptance (1=excellent, 2=good, 3=fair, 4=poor)
Time Frame: During pediatric procedural sedation (up to 3 hour)
|
Patients' acceptance (1=excellent, 2=good, 3=fair, 4=poor)
|
During pediatric procedural sedation (up to 3 hour)
|
Separation anxiety (1=easy, 2=whimper, 3=cry, 4=cry and cling to parents)
Time Frame: During pediatric procedural sedation (up to 3 hour)
|
Separation anxiety (1=easy, 2=whimper, 3=cry, 4=cry and cling to parents)
|
During pediatric procedural sedation (up to 3 hour)
|
Physicians' satisfaction (1=excellent, 2=good, 3=fair, 4=poor)
Time Frame: During pediatric procedural sedation (up to 3 hour)
|
Physicians' satisfaction (1=excellent, 2=good, 3=fair, 4=poor)
|
During pediatric procedural sedation (up to 3 hour)
|
Total cost of sedation (KRW)
Time Frame: During pediatric procedural sedation (up to 1 day)
|
Total cost of sedation (KRW)
|
During pediatric procedural sedation (up to 1 day)
|
Onset time of rescue sedation (PSSS =1,2,3) (min)
Time Frame: During pediatric procedural sedation (up to 3 hour)
|
Onset time of rescue sedation (Pediatric Sedation State Scale= 1,2,3) after rescue sedative administration.
|
During pediatric procedural sedation (up to 3 hour)
|
Duration of rescue sedation = Recovery time (PSSS =4,5)
Time Frame: During pediatric procedural sedation (up to 3 hour)
|
Pediatric Sedation State Scale= 4,5 after recovery of sedation
|
During pediatric procedural sedation (up to 3 hour)
|
HR during sedation (/min)
Time Frame: During pediatric procedural sedation (up to 3 hour)
|
HR(/min) at Baseline(T0), q 10min
|
During pediatric procedural sedation (up to 3 hour)
|
The incidence of respiratory intervention: Manual ventilation or Artificial airway %
Time Frame: During pediatric procedural sedation (up to 3 hour)
|
The incidence of respiratory intervention: Manual ventilation or Artificial airway %
|
During pediatric procedural sedation (up to 3 hour)
|
The incidence of Other side effects (Ex: Nausea/Vomit, Allergic reaction, Etc)
Time Frame: During pediatric procedural sedation (up to 3 hour)
|
The incidence of Other side effects (Ex: Nausea/Vomit, Allergic reaction, Etc)
|
During pediatric procedural sedation (up to 3 hour)
|
The incidence of Rescue sedation failure (PSSS =0,4,5) after 30 min %
Time Frame: During pediatric procedural sedation (up to 3 hour)
|
The incidence of Rescue sedation failure (PSSS =0,4,5) after 30 min %
|
During pediatric procedural sedation (up to 3 hour)
|
The incidence of Completion of procedure
Time Frame: During pediatric procedural sedation (up to 3 hour)
|
The incidence of Completion of procedure
|
During pediatric procedural sedation (up to 3 hour)
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Sheta SA, Al-Sarheed MA, Abdelhalim AA. Intranasal dexmedetomidine vs midazolam for premedication in children undergoing complete dental rehabilitation: a double-blinded randomized controlled trial. Paediatr Anaesth. 2014 Feb;24(2):181-9. doi: 10.1111/pan.12287. Epub 2013 Nov 15.
- Zanaty OM, El Metainy SA. A comparative evaluation of nebulized dexmedetomidine, nebulized ketamine, and their combination as premedication for outpatient pediatric dental surgery. Anesth Analg. 2015 Jul;121(1):167-171. doi: 10.1213/ANE.0000000000000728.
- Zhang W, Wang Z, Song X, Fan Y, Tian H, Li B. Comparison of rescue techniques for failed chloral hydrate sedation for magnetic resonance imaging scans--additional chloral hydrate vs intranasal dexmedetomidine. Paediatr Anaesth. 2016 Mar;26(3):273-9. doi: 10.1111/pan.12824. Epub 2015 Dec 30.
- Cao Q, Lin Y, Xie Z, Shen W, Chen Y, Gan X, Liu Y. Comparison of sedation by intranasal dexmedetomidine and oral chloral hydrate for pediatric ophthalmic examination. Paediatr Anaesth. 2017 Jun;27(6):629-636. doi: 10.1111/pan.13148. Epub 2017 Apr 17.
- Zhang W, Fan Y, Zhao T, Chen J, Zhang G, Song X. Median Effective Dose of Intranasal Dexmedetomidine for Rescue Sedation in Pediatric Patients Undergoing Magnetic Resonance Imaging. Anesthesiology. 2016 Dec;125(6):1130-1135. doi: 10.1097/ALN.0000000000001353.
- Jun JH, Kim KN, Kim JY, Song SM. The effects of intranasal dexmedetomidine premedication in children: a systematic review and meta-analysis. Can J Anaesth. 2017 Sep;64(9):947-961. doi: 10.1007/s12630-017-0917-x. Epub 2017 Jun 21.
- Abdel-Ghaffar HS, Kamal SM, El Sherif FA, Mohamed SA. Comparison of nebulised dexmedetomidine, ketamine, or midazolam for premedication in preschool children undergoing bone marrow biopsy. Br J Anaesth. 2018 Aug;121(2):445-452. doi: 10.1016/j.bja.2018.03.039. Epub 2018 Jun 22.
- Poonai N, Canton K, Ali S, Hendrikx S, Shah A, Miller M, Joubert G, Rieder M, Hartling L. Intranasal ketamine for procedural sedation and analgesia in children: A systematic review. PLoS One. 2017 Mar 20;12(3):e0173253. doi: 10.1371/journal.pone.0173253. eCollection 2017.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Dissociative
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Analgesics, Non-Narcotic
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Hypnotics and Sedatives
- Ketamine
- Dexmedetomidine
- Chloral Hydrate
Other Study ID Numbers
- IN DEXKET rescue
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sedation
-
I.M. Sechenov First Moscow State Medical UniversityCompleted
-
Davinia WithingtonUnknownSedation | Mechanical Ventilation | Daily Sedative Interruption | Sedation Strategies | Sedation ProtocolsCanada
-
University Hospital Inselspital, BerneGE HealthcareCompletedCritical Care | Conscious Sedation | Deep SedationSwitzerland
-
Seoul National University HospitalRecruiting
-
National Taiwan University HospitalCompleted
-
Paion UK Ltd.Premier Research Group plcCompleted
-
Washington University School of MedicineWithdrawn
Clinical Trials on Intranasal dexmedetomidine and ketamine
-
Guangzhou Women and Children's Medical CenterSuspendedIntranasal Ketamine With Dexmedetomidine for the Treatment of Children With Autism Spectrum DisorderAutism Spectrum DisorderChina
-
University of OklahomaRecruitingAnxiety | Laceration of Skin | Discharge TimeUnited States
-
Ciusss de L'Est de l'Île de MontréalRecruiting
-
University of CincinnatiUnknownDepression | Suicidal Ideation | Suicidal ImpulsesUnited States
-
Groupe Oncologie Radiotherapie Tete et CouSchering-PloughCompletedHead and Neck CancerFrance
-
Children's Hospital Medical Center, CincinnatiCompletedHeart DiseaseUnited States
-
Washington University School of MedicineCompletedHead and Neck Cancer
-
Kythera BiopharmaceuticalsCompletedEfficacy | Safety | Moderate to Severe Convexity of Submental FatUnited States
-
Jiangsu HengRui Medicine Co., Ltd.Unknown